Condition: Retinal Dystrophy Due to Biallelic ABCA4 Mutations · Stargardt Disease 1 · Sponsor: VeonGen Therapeutics GmbH
This is a single-arm, open-label, non-randomized, single dose-escalation, first-in-human (FIH) clinical trial to evaluate the safety and preliminary efficacy of VG801 for treatment of patients with retinal dystrophy (Stargardt disease) due to biallelic ABCA4 mutations.
This description comes directly from the study's public registry record.
Research Coordinator · +86-021-36123569 · shiyilunli@sina.com
Always discuss trial participation with your own doctor first.
| Shanghai General Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07002398